345 results about "Biosynthetic genes" patented technology

A method of producing coryneform bacteria having improved amino acid or nucleic acid productivity comprising the steps of introducing a mutation in a promoter sequence of amino acid- or nucleic acid-biosynthesizing genes on a chromosome of a coryneform bacterium to make it close to a consensus sequence, or introducing a change in a promoter sequence of amino acid- or nucleic acid-biosynthesizing genes on a chromosome of a coryneform bacterium by gene recombination to make it close to a consensus sequence, to obtain mutants of the coryneform amino acid- or nucleic acid-producing microorganism, culturing the mutants and selecting a mutant capable of producing the intended amino acid or nucleic acid in a large amount. This method allows the construction of a mutant capable of enriching or controlling the expression of an intended gene without using a plasmid and to promote production of amino acids in a high yield by recombination or mutation.

Methods for engineering transgenic organisms that synthesize polyhydroxyalkanoates (PHAs) containing 3-hydroxyhexanoate as comonomer have been developed. These processes are based on genetically engineered bacteria such as Escherichia coli or in plant crops as production systems which include PHA biosynthetic genes from PHA producers. In a preferred embodiment of the method, additional genes are introduced in wild type or transgenic polyhydroxybutyrate (PHB) producers, thereby creating new strains that synthesize 3HH monomers which are incorporated into PHAs. The 3HH monomer preferably is derived in microbial systems using butanol or butyrate as feedstocks, which are precursors of 3-hydroxyhexanoyl-CoA. Pathways for in vivo production of butyrol-CoA specifically encompassing butyryl-CoA dehydrogenase activity are provided.

The present invention relates to gram-negative bacterial mutants resistant to one or more stress conditions, including, but not limited to, CO₂, acid pH, and high osmolarity. The present invention also relates more particularly to gram-negative bacterial mutants with reduced TNF-α induction having a mutation in one or more lipid biosynthesis genes, including, but not limited to msbB, that are rendered stress-resistant by a mutation in the zwf gene. The present invention provides compositions comprising one or more stress-resistant gram-negative bacterial mutants, preferably attenuated stress-resistant gram-negative bacterial mutants. In particular, the present invention relates to methods for prophylaxis or treatment of a virally induced disease in a subject comprising administering to said subject one or more stress-resistant gram-negative bacterial mutants, preferably attenuated stress-resistant gram-negative bacterial mutants. The present invention further relates to methods for prophylaxis or treatment of a virally induced disease in a subject comprising administering to said subject one or more stress-resistant gram-negative bacterial mutants as vectors for the delivery of one or more therapeutic molecules. The methods of the invention provide more efficient delivery of therapeutic molecules by stress-resistant gram-negative bacterial mutants engineered to express said therapeutic molecules.

A unique carotenogenic biosynthetic gene cluster has been isolated from Panteoa agglomerans strain DC404, wherein the genetic organization of the cluster is crtE-idi-crtY-crtI-crtB-crtZ. The genes contained within this cluster encode geranylgeranyl pyrophosphate (GGPP) synthetase (CrtE), isopentenyl pyrophosphate isomerase (Idi), lycopene cyclase (CrtY), phytoene desaturase (CrtI), phytoene synthase (CrtB), and β-carotene hydroxylase (CrtZ). The gene cluster, genes and their products are useful for the conversion of farnesyl pyrophosphate to carotenoids. Vectors containing those DNA segments, host cells containing the vectors and methods for producing those enzymes by recombinant DNA technology in transformed host organisms are disclosed.

The present invention relates to gram-negative bacterial mutants resistant to one or more stress conditions, including, but not limited to, CO₂, acid pH, and high osmolarity. The present invention also relates more particularly to gram-negative bacterial mutants with reduced TNF-α induction having a mutation in one or more lipid biosynthesis genes, including, but not limited to msbB, that are rendered stress-resistant by a mutation in the zwf gene. The present invention provides compositions comprising one or more stress-resistant gram-negative bacterial mutants, preferably attenuated stress-resistant gram-negative bacterial mutants. In particular, the present invention relates to methods for prophylaxis or treatment of a virally induced disease in a subject comprising administering to said subject one or more stress-resistant gram-negative bacterial mutants, preferably attenuated stress-resistant gram-negative bacterial mutants. The present invention further relates to methods for prophylaxis or treatment of a virally induced disease in a subject comprising administering to said subject one or more stress-resistant gram-negative bacterial mutants as vectors for the delivery of one or more therapeutic molecules. The methods of the invention provide more efficient delivery of therapeutic molecules by stress-resistant gram-negative bacterial mutants engineered to express said therapeutic molecules.

The present invention provides methods and DNA constructs for the genetic engineering of plant cells to produce plants which produce substantially seedless fruit in the absence of exogenous growth factors (auxins or cytokinins) and in the absence of pollination. The substantially seedless fruits produced by the methods described herein are about the size of wildtype seeded fruit (or somewhat larger) and these fruits are equal to or superior to the wildtype seeded fruit with respect to solid content and flavor. The seedless fruits of the present invention are produced in transgenic plants which contain and express auxin or cytokinin biosynthetic genes, e.g., tryptophan oxygenase or isopentenyl transferase coding sequences expressed under the regulatory control of GH3 or AGL promoter sequences directing preferential or tissue specific expression of a downstream gene in the ovaries or developing fruit.

The invention relates to a recombinant DNA (deoxyribonucleic acid), strain and method for producing L-valine by fermentation. The recombinant DNA comprises DNA sequence for coding acetohydroxy acid synthetase free of feedback inhibition of three branched-chain amino acids to acetohydroxy acid synthetase, DNA sequence for coding dihydroxy reduction isomerase, and DNA sequence for coding branched-chain amino acid aminotransferase. The strain is corynebacterium or brevibacterium transformed by introducing the recombinant DNA. The method is implemented by culturing the strain to produce the L-valine. In the invention, the expression L-valine is used for producing the bacterium L-valine biosynthetic gene, so the yield of the L-valine can be greatly increased; and the fermentation model, especially the high-temperature short-time fermentation model, is constructed according to the optimum temperature of the L-valine biosynthetic enzyme, so that the metabolism intensity of the strain is enhanced, the activity of the L-valine biosynthetic enzyme is enhanced, and the yield of the L-valine and the conversion rate of the sugar acid can be further increased.

The present invention refers to the gene cluster and genes comprised by the gene cluster which are involved in the biosynthesis of griselimycin and methylgriselimycin and to the use of the gene cluster, genes comprised thereby and proteins encoded thereby for the production of antibiotic agents.

The present invention provides an approach to increase yield and vigor in a plant. The present invention describes expressing a heterologous gene in a plant that control cytokinin expression under the control of a cell cycle regulated promoter.

The present invention provides cloning sequencing, analyzing, function research of a biosynthesis gene cluster of an antibiotic-Azinomycin B having antitumor activity produced by streptomyces, and its application. The whole gene cluster includes 34 genes: one repeatedly using I type polyketide synthase gene; two naphthalene ring modification enzyme genes; 8 non-ribosomal polypeptide skeleton synthesis and modification enzyme genes; 11 non-natural amino acid structure unit synthase genes; 1 resistance gene; 3 post modification enzyme genes and 8 genes which functions are not determined. The genetic operation of the biosynthesis gene breaks the synthesis of Azinomycin B; the precursor compound is produced by the heterologous expression of synthesis gene and modification gene of naphthalene ring. The gene of the invention and the protein can be used for searching and finding compound or gene, protein applied in medical, industry or agriculture.

The invention provides methods and materials relating generally to plant derived flavin-containing monooxygenases (FMOs) capable of catalysing oxidation of a thio- to a sulphinyl-group during glucosinolate biosynthesis. It further relates to plant derived MYB factors capable of transcriptional regulation of biosynthetic genes. These have utility in the modification of glucosinolate biosynthesis.

The invention discloses a biosynthetic gene cluster of romatic-polyketide atypical fluostatins and applications thereof. The nucleotide sequence of the biosynthetic gene cluster of fluostatins derived from micromonospora rosaria SCSIO N160 (preservation No: CCTCC NO: M2012392) is shown in the 1st-40128th base sequences in SEQ ID NO. 1, and contains 32 genes. Genes and proteins thereof provided by the invention can be used for seeking and finding compounds or genes and proteins for medicine, industry or agriculture.

The present invention relates to a method for the production of unsaturated fatty acids with at least two double bonds. The invention furthermore relates to the use of nucleic acid sequences SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 and SEQ ID NO: 11 encoding polypeptides having desaturase activity in the method and for generating a transgenic organism, preferably a transgenic plant or a transgenic microorganism, with an increased content of fatty acids, oils or lipids with unsaturated C₁₈-, C₂₀-, or C₂₂-fatty acids, and to their homologs or derivatives, to gene constructs encompassing these genes, and to their use alone or in combination with biosynthesis genes of polyunsaturated fatty acids. The invention also relates to multiexpression cassettes for seed-specific expression, and to vectors or organisms which encompass a desaturase gene alone or in combination with further desaturases and/or elongase genes or homologs using said expression cassettes.

The invention relates to IMP (inosine monophosphate) dehydrogenase synthesized by 'Bailing' producing fungus Chinese caterpillar fungus hirsutella sinensis to metabolize guanine nucleotide based on xanthosine monophosphate and coding genes and application of the IMP dehydrogenase. The IMP dehydrogenase comprises proteins shown by SEQ ID No.1, SEQ ID No.2 and SEQ ID No.3, and coding genes of the IMP dehydrogenase correspond to nucleotide sequences shown by SEQ ID No.4, SEQ ID No.5 and SEQ ID No.6. Detailed studies on metabolic pathways of the xanthosine monophosphate synthesizing the guanine nucleotide in principle are carried out and include that cloned DNAs (deoxyribonucleic acids) in the provided nucleotide sequences can be transferred into engineering bacteria by means of transduction, transformation and transconjunction, and high expressivity is given to the host guanine nucleotide by adjusting expressions of guanine nucleotide biosynthetic genes, so that an effective way for increasing output of the guanine nucleotide is provided, and the IMP dehydrogenase and the coding genes have significant application prospects.

Provided is a method for expressing an introduced gene or genes in a C1 metabolizing microorganism host wherein the gene(s) are integrated into the tig region of the chromosome. This method provides high level expression in a stable manner in which growth rate of the host strain is not highly affected and a selection marker is not required. The use of this method for expressing carotenoid biosynthetic genes and resulting production of canthaxanthin is also described.

The invention discloses a biosynthetic gene cluster of grincamycin and P-1894B and application thereof. The nucleotide sequence of the biosynthetic gene cluster of grincamycin and P-1894B is shown as the base sequences from 3722-40612 of SEQ ID NO.1. The biosynthesis-associated all gene and protein information containing grincamycin and P-1894B provided by the invention can help people to understand the biosynthetic mechanism of angucycline natural products so as to provide materials and knowledge for further genetic modification. The gene and the protein provided by the invention can be used for seeking for and discovering compounds or genes and proteins which can be applied to medicines, industry or agriculture.

The invention discloses a biosynthetic gene cluster of paquete amide and an application thereof. The biosynthetic gene cluster of paquete amide comes from (Streptomyces pactum)SCSIO 02999, and the cluster comprises five genes including heterozygous polyketone/ nonribosomal peptide synthetases genes ptmA, FAD dependent redox enzyme genes ptmB1, phytoene dehydrogenase genes ptmB2, cyclase genes ptmC and hydroxylase genes ptmD. According to the biosynthetic gene cluster of paquete amide and the application thereof, information in genes and proteins related to biosynthesis of the paquete amide provides theoretical foundations and materials for conducting genetic modification on the biosynthesis of multi-ring tetramate macrocylic lactam family. By conducting genetic modifications on the biological synthetic genes, 6 new structures antineoplastic paquete amide compounds pactamide A-F are obtained, and thus effective compound entities are provided for research and development of antineoplastic drugs.

The invention discloses cloning, sequencing, analysis, function study and application of a biosynthesis gene cluster of a novel anti-microbial and anti-tumor compound WSS2277 in the field of biotechnologies. The gene cluster comprises nucleotide sequences of twenty-one genes or complementary sequences which are formed by the sequences 1, wherein the fourteen genes including siaA, siaB1, siaB2, siaC, siaD, siaE, siaF, siaG, siaH, siaI, siaJ, siaK, siaL and siaM are responsible for the synthesis of a carbon skeleton, and the seven genes incluidng siaN, siaO, siaP, siaQ, siaR, siaS and siaT are responsible for regulating biosynthesis. The information of the genes which are related to the biosynthesis of the WSS2277 is provided by the invention, and a foundation is provided for the study and the genetic modification of the biosynthesis of the WSS2277. A novel structural analogue can be generated through the modification of carbon skeleton synthesis genes in the WSS2277, and the yield of the WSS2277 or a derivative thereof can be provided through the interruption or the high replication of regulator genes in the WSS2277. The genes and proteins, which are provided by the invention, can also be used for searching and discovering compounds or genes and proteins, which can be applied to the fields of medicine, industry or agriculture.

The invention relates to the cloning, sequencing, analyzing, functional study of biological synthetic gene cluster of erythromycin produced by streptomycete in tetrahydroisoquinoline alkaloid family which has the antineoplastic activity and application thereof. The whole gene cluster contains 30 genes: 3 nonribosome polypeptide synthetase genes, 4 antecedent molecule synthetic genes of 3-hydroxy-5-methyl-O-methyl-tyrosine, 2 peptid ring skeleton synthetic genes, 7 erythromycin modifying genes, 5 genes related to S-adenosine methionine synthesis, 3 regulation genes, 2 resistance genes and 4 genes with uncertain function. Genetic manipulation of the genes can block the synthesis of erythromycin, change the output and get analogue of erythromycin. The gene cluster can be used for gene engineering, protein expression, enzymic catalytic reaction, etc. of tetrahydroisoquinoline alkaloid family and finding out compounds or genes being suitable for medicine, industry or agriculture.

The present invention belongs to the field of antibiotic gene engineering, and is especially the process of cloning nicomycin biological synthetic gene sanU from one strain of Streptomyces ansochromogenes 7100 CGMCC 4.321; connecting the synthetic gene sanU with promoter of melanin biosynthetic structure gene, cloning onto the polycloning site of integrative single-copy plamid, transforming wild Streptomyces ansochromogenes 7100 CGMCC 4.321 protoplast to obtain nicomycin X component of the recombinant engineering bacterium in the yield 2 times higher than wild strain. The high-yield engineering bacterium may be used in preparing antiseptic medicines.

The invention relates to a clone, sequencing, analysis and function study of biosynthesis gene cluster of antibiotics-Tectrocarcin A which has anti-tumor activity and is generated by Micromonospora chalcea NRRL11289 and the application thereof. The whole gene cluster contains 36 genes: 5 non-reused I type polyketone synthetase genes; 4 special three-carbon biosynthesis genes; 11 desoxy sugar biosynthesis genes; 9 post modifying genes; 2 regulator genes; 1 resistance gene; and 4 genes with uncertain function. Due to the genetic manipulation of biosynthesis genes, the biosynthesis of Tectrocarcin A can be prevented. The genes and the proteins thereof which are provided by the invention can also be used for searching and discovering the compounds, genes or proteins that can be applies in medicine, industry or agriculture.

The invention discloses a biosynthetic gene cluster of phoslactomycins produced by Streptomyces platensis SAM-0654. The whole gene cluster contains twenty twelve genes as follows: seven I-type linear polyketone synthetase (PKS) genes, two ethylmalonyl CoA synthetase genes, four cyclohexylformyl-CoA synthetase genes, six post-modified enzyme genes, two regulation genes and a resistance gene. Through carrying out genetic operation on the biosynthetic gene cluster, the synthesis of the phoslactomycins can be blocked. The gene cluster provided by the invention can be used for output variation of the phoslactomycins, combination generation of polyketone compounds and the like, and also can be used for searching and finding compounds or genes for medicine, industry or agriculture.